D-Ribose

D-ribose sits at the start of the pentose phosphate pathway and is the sugar backbone of ATP, NAD, and RNA. When tissue adenine nucleotide pools are severely depleted — after ischaemia, in some rare metabolic myopathies, or in failing myocardium — resynthesis is slow because the body must build ribose-5-phosphate from glucose, a rate-limited step. Supplying ribose directly bypasses that bottleneck. That is the mechanism, and it is sound.

The clinical picture is narrower than the mechanism suggests. In myoadenylate deaminase deficiency, ribose reduces exercise-induced cramping and stiffness, and this remains its most credible indication. In chronic heart failure, small crossover trials reported improved diastolic function and better quality-of-life scores, but sample sizes were under 40 and larger confirmatory trials have not been run. In fibromyalgia and chronic fatigue, the widely-cited energy improvements come from an open-label study without a placebo arm, which in a condition with large placebo responses is not persuasive.

In healthy athletes the answer is clearer and negative: multiple controlled trials of 10 g per day or more found no improvement in power output, sprint performance, or recovery. Healthy muscle simply does not have depleted ATP pools to rescue. Ribose is also a genuinely reactive sugar, glycating proteins faster than glucose in laboratory conditions, which is a reason to avoid open-ended high-dose use.